Pfizer and Valneva report mixed results for Lyme disease vaccine, with one analysis narrowly missing efficacy

New data on the collaborative Lyme disease vaccine from Pfizer and Valneva were presented, showing divergent outcomes across two key analyses. One analysis met its predefined endpoints, while the other fell just short, creating a near‑miss scenario.

The mixed readout leaves the vaccine's commercial prospects uncertain, as stakeholders weigh the implications of the borderline result. No additional efficacy or safety numbers were disclosed in the brief summary.

Analysts note that the outcome could affect future investment and development decisions for both companies, especially given the high unmet need for a Lyme disease preventive.

The companies have not indicated any changes to their development timeline, but the data suggest further evaluation may be required before a definitive regulatory filing can be pursued.